Myeloid Therapeutics is an immunology company focused on combining biology insights with cutting-edge technologies to harness myeloid cells and eradicate cancer and other diseases. We’re passionate about scientific inquiry, collaborating to solve big clinical problems, and most of all, helping patients.
Myeloid is powered by our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery. And we are working to build a team of talented, driven scientists and other biotech industry experts, who will turn these discoveries into novel, lifesaving treatments for patients.
Our ATAKTM platform integrates the accumulated know-how and experience of our founders and our growing research team, to deliver new products that reprogram innate immune cells to eradicate disease. We have built a platform manufacturing process that reduces cell handling to less than one day, and supports the rapid translation of the company’s lead assets to the clinic: MT-101 for peripheral and cutaneous forms of T cell Lymphoma, MT-102 for HER2 expressing solid tumors, MT-103 for TROP2 expressing solid tumors, and MT-201, our primed monocyte that stimulates T cells to fight glioblastoma. We expect to initiate clinical trials for several of these product candidates in the first half of 2021, a mere 18-months from our founding.
We invite you to join us on this journey – patients are waiting.
– Daniel Getts, CEO
Myeloid is powered by our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery. And we are working to build a team of talented, driven scientists and other biotech industry experts, who will turn these discoveries into novel, lifesaving treatments for patients.
Our ATAKTM platform integrates the accumulated know-how and experience of our founders and our growing research team, to deliver new products that reprogram innate immune cells to eradicate disease. We have built a platform manufacturing process that reduces cell handling to less than one day, and supports the rapid translation of the company’s lead assets to the clinic: MT-101 for peripheral and cutaneous forms of T cell Lymphoma, MT-102 for HER2 expressing solid tumors, MT-103 for TROP2 expressing solid tumors, and MT-201, our primed monocyte that stimulates T cells to fight glioblastoma. We expect to initiate clinical trials for several of these product candidates in the first half of 2021, a mere 18-months from our founding.
We invite you to join us on this journey – patients are waiting.
– Daniel Getts, CEO
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $123M
Founded date: 2019
Investors 3
| Date | Name | Website |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | 8VC | 8vc.com |
| - | Newpath Ma... | newpath.pa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.05.2023 | - | $73M | ARCH Ventu... |
| 06.01.2021 | Series C | $50M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Daniel | Geffken | Senior Fin... | linkedin.c... | - | - |
Mentions in press and media 9
| Date | Title | Description |
| 03.02.2025 | This Startup Is Billionaire Reid Hoffman's Next Big Bet Hoffman sold LinkedIn, which he co-founded, to Microsoft for $26.2 billion in 2016. | LinkedIn co-founder Reid Hoffman became a billionaire when Microsoft bought LinkedIn in 2016 for $26.2 billion in cash, and he has also made his fortune on high-return investments in more than 80 tech startups, including Airbnb, Groupon, an... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 18.05.2023 | Myeloid Therapeutics Raises $73M in Financing | Myeloid Therapeutics, a Cambridge, CA-based clinical stage mRNA-immunotherapy company, raised $73M in funding. The round was led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategi... |
| 06.01.2021 | Myeloid Therapeutics Raises Over $50M in Financing | Myeloid Therapeutics, Inc., a Cambridge, Mass.-based company harnessing and reprogramming myeloid cells for treating cancers, launched with over $50m in financing. The round was led by Newpath Partners with participation from 8VC, Hatteras ... |
| 06.01.2021 | Myeloid Therapeutics Raises Over $50M in Financing | Myeloid Therapeutics, Inc., a Cambridge, Mass.-based company harnessing and reprogramming myeloid cells for treating cancers, launched with over $50m in financing. The round was led by Newpath Partners with participation from 8VC, Hatteras ... |
| 06.01.2021 | Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials | |
| 06.01.2021 | Myeloid Therapeutics Raises Over $50M in Financing | Myeloid Therapeutics, Inc., a Cambridge, Mass.-based company harnessing and reprogramming myeloid cells for treating cancers, launched with over $50m in financing. The round was led by Newpath Partners with participation from 8VC, Hatteras ... |
| - | Acute myeloid leukemia drugmaker closes $14.2M, focuses on personalized medicine | Tolero Pharmaceuticals, a Salt Lake City, Utah drug developer, has set its sights on ramping up the commercialization and development efforts of its acute myeloid leukemia treatment, which will enter Phase 3 trial sometime next year. The co... |
| - | Myeloid Therapeutics | “The Leaders in mRNA-based Immunotherapies. Our therapies incorporate advanced cell and gene therapy methods to improve the lives of patients.” |